… pts in the intent-to-treat analysis. Pts who reported never smoking in the erlotinib arm (n=69) …
Conclusions: Although erlotinib with CP did not confer an advantage in OS over CP alone in …

… to conduct sub-group analyses, immature … erlotinib plus bevacizumab compared to
erlotinib monotherapy in EGFR-positive NSCLC patients was investigated in two other meta-analyses…

… Erlotinib is the first of this novel class of drug to demonstrate a … and clinical data to support
the use of erlotinib in NSCLC. … analysis for treatment with erlotinib has not been reported. …

… therapy, and the small number of included studies, negating the possibility of exploring
possible sub-group analyses and exploring heterogeneity among study populations. …

… preplanned sub-group analyses suggested survival benefits in patients of Oriental origin
and in patients who had never smoked, for gefitinib and placebo, respectively Citation[13]. …

… In summary, the results of this study show that erlotinib has significant antitumor activity in
the first-line treatment of advanced NSCLC, which may be comparable with single-agent …

… Ongoing trials of erlotinib given after four cycles of platinum-… of erlotinib with chemotherapy
will clarify the role of erlotinib … The mutation analyses are reviewed by a team of 17 surgical …

Frontiers | Effectiveness and safety of the bevacizumab and erlotinib combination versus
erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and …

… meta-analysis showed that erlotinib … -analysis compared the survival advantages of gefitinib
combined with chemotherapy and chemotherapy alone for NSCLC. The sub-group analyzed …

… -analysis of fatal pulmonary events associated with erlotinib, … Our meta-analysis has
demonstrated that erlotinib, gefitinib … of ILD was found in sub-group analysis according to …